Search

everythinglearnresearchcommunity

for

Search:↓

The treatment showed significant hair regrowth in alopecia areata patients without side effects.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Alitretinoin helped clear up a skin condition called generalized granuloma annulare in an elderly man.

Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

MTX and GC combinations are the most effective for early rheumatoid arthritis.

Upadacitinib improved multiple immune-related conditions in one patient.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Many patients with Giant Cell Arteritis did not follow their steroid treatment plans properly.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Troglitazone increases subcutaneous fat in lipodystrophy patients.

Ritlecitinib is effective for long-term treatment of severe alopecia areata.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.